Summary

The 7 major sarcopenia markets reached a value of US$ 1.5 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.3 Billion by 2034, exhibiting a growth rate (CAGR) of 4.1% during 2024-2034.

The sarcopenia market has been comprehensively analyzed in IMARC's new report titled "Sarcopenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Sarcopenia refers to a medical condition characterized by the progressive loss of muscle mass, strength, and function that occurs as a natural part of the aging process. It is often caused by a misalignment of signals for muscle cell growth and breakdown, resulting in reduced quality of life, fractures, falls, and disability. The most prominent symptom of sarcopenia is muscle weakness. Individuals suffering from this condition may also experience loss of stamina, difficulty performing daily activities, trouble climbing stairs, poor balance and falls, decrease in muscle size, etc. The diagnosis of the ailment is based on a review of the patient's clinical features, medical history, and physical exam. The healthcare professional may additionally perform muscle strength studies, including handgrip test, chair stand test, short physical performance battery, walking speed exam, timed-up and go test, etc. In some cases, a dual-energy X-ray absorptiometry (DEXA), which uses low-power X-rays to measure muscle mass, fat, and bone density, is also recommended to confirm a diagnosis.

The expanding geriatric population, who are more susceptible to changes in the number and size of muscle fibers, is primarily driving the sarcopenia market. In addition to this, the increasing incidences of several associated risk factors, including sedentary lifestyle, obesity, hormonal imbalance, inadequate protein intake, neurological disorders, etc., are further augmenting the market growth. Moreover, the emerging popularity of effective medications, such as β-hydroxy β-methyl butyrate, which acts as a signaling molecule to enhance protein synthesis and prevent loss of lean body mass, is also creating a positive outlook for the market. Apart from this, the widespread adoption of bioelectrical impedance analysis for diagnosing the disease owing to its numerous benefits, including minimal invasion, portability, ease of use, relatively low cost, safety, etc., is further bolstering the market growth. Additionally, the escalating utilization of resistance and strength training to treat the condition by increasing muscle protein synthesis and supporting muscular strength is acting as another significant growth-inducing factor. Besides this, the rising usage of myostatin inhibitors that can promote healthy muscle mass and improve mobility in patients is expected to drive the sarcopenia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the sarcopenia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for sarcopenia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the sarcopenia market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the sarcopenia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the sarcopenia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current sarcopenia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the sarcopenia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the sarcopenia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the sarcopenia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of sarcopenia across the seven major markets?
What is the number of prevalent cases (2018-2034) of sarcopenia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of sarcopenia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with sarcopenia across the seven major markets?
What is the size of the sarcopenia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of sarcopenia?
What will be the growth rate of patients across the seven major markets?

Sarcopenia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for sarcopenia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the sarcopenia market?
What are the key regulatory events related to the sarcopenia market?
What is the structure of clinical trial landscape by status related to the sarcopenia market?
What is the structure of clinical trial landscape by phase related to the sarcopenia market?
What is the structure of clinical trial landscape by route of administration related to the sarcopenia market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Sarcopenia - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034​)
4.4 Market Overview (2018-2023) and Forecast (2024-2034​)
4.5 Competitive Intelligence

5 Sarcopenia - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Sarcopenia - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034​)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034​)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034​)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034​)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034​)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034​)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034​)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034​)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)

8 Sarcopenia - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Sarcopenia - Unmet Needs

10 Sarcopenia - Key Endpoints of Treatment

11 Sarcopenia - Marketed Products
11.1 List of Sarcopenia Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 Sarcopenia - Pipeline Drugs
12.1 List of Sarcopenia Pipeline Drugs Across the Top 7 Markets
12.1.1 MYMD 1 - MyMD Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 BIO101 - Biophytis
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Sarcopenia - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Sarcopenia – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Sarcopenia - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Sarcopenia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034​)
15.2.2 Sarcopenia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034​)
15.3 Market Scenario - United States
15.3.1 Sarcopenia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034​)
15.3.2 Sarcopenia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034​)
15.3.3 Sarcopenia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Sarcopenia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034​)
15.4.2 Sarcopenia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034​)
15.4.3 Sarcopenia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Sarcopenia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034​)
15.5.2 Sarcopenia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034​)
15.5.3 Sarcopenia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Sarcopenia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034​)
15.6.2 Sarcopenia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034​)
15.6.3 Sarcopenia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Sarcopenia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034​)
15.7.2 Sarcopenia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034​)
15.7.3 Sarcopenia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Sarcopenia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034​)
15.8.2 Sarcopenia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034​)
15.8.3 Sarcopenia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Sarcopenia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034​)
15.9.2 Sarcopenia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034​)
15.9.3 Sarcopenia - Access and Reimbursement Overview

16 Sarcopenia - Recent Events and Inputs From Key Opinion Leaders

17 Sarcopenia Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Sarcopenia Market – Strategic Recommendations

19 Appendix